NCT03428126 - Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

May 5, 2022

Study Completion Date

May 5, 2022

Conditions

Malignant Neoplasms of Digestive OrgansColorectal CancerColon Cancer

Interventions

DRUG

Durvalumab

Dose Escalation and Dose Expansion Dose: 1500 mg by vein every 4 weeks in a 28 day cycle.

DRUG

Trametinib

"Dose Escalation Starting Dose: 2mg by mouth daily in a 28 day cycle.~Dose Expansion Dose: MTD from Dose Escalation."

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston